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PodocyteThe pathophysiology of glomerular lesions ofmembranous nephropathy (MN), including seldom-reported IgG4-
related disease, is still elusive. Unlike in idiopathicMNwhere IgG4 prevails, in this patient IgG3was predominant
in glomerular deposits in the absence of circulating anti-phospholipase A2 receptor antibodies, suggesting a
distinct pathologic process. Here we documented that IgG4 retrieved from the serum of our propositus reacted
against carbonic anhydrase II (CAII) at the podocyte surface. In patient's biopsy, glomerular CAII staining
increased and co-localized with subepithelial IgG4 deposits along the capillary walls. Patient's IgG4 caused a
drop in cell pH followed bymitochondrial dysfunction, excessive ROS production and cytoskeletal reorganization
in cultured podocytes. These events promotedmitochondrial superoxide-dismutase-2 (SOD2) externalization on
the plasma membrane, becoming recognizable by complement-binding IgG3 anti-SOD2. Among patients with
IgG4-related disease only sera of those with IgG4 anti-CAII antibodies caused low intracellular pH andmitochon-
drial alterations underlying SOD2 externalization. Circulating IgG4 anti-CAII can cause podocyte injury through
processes of intracellular acidiﬁcation, mitochondrial oxidative stress and neoantigen induction in patients
with IgG4 related disease. The onset of MN in a subset of patients could be due to IgG4 antibodies recognizing
CAII with consequent exposure of mitochondrial neoantigen in the context of multifactorial pathogenesis of
disease.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hyper-IgG4-associated abnormalities are common denominators
for several autoimmune ﬁbroinﬂammatory diseases that can affect any
organ from the salivary glands to the pancreas or kidneys, collectively
referred to as IgG4-related disease [1]. Characteristic pathological
features in various affected sites consist of lymphoplasmacytic inﬁltra-
tion with IgG4-positive plasma cells, storiform ﬁbrosis, and variably
elevated levels of IgG4 [1]. Kidney lesions are usually accompanied by
tubulointerstitial nephritis [2]. Glomerular lesions, including membra-
nous nephropathy (MN), have been reported less frequently [2,3].Farmacologiche “Mario Negri”,
Kilometro Rosso, Via Stezzano,
emuzzi).
. This is an open access article underWe described a 54-year-old male patient with IgG4-related disease
manifesting as pancreatitis, Mikulicz disease that later developed
nephrotic-range proteinuria, and MN [4] with glomerular lesions partly
different from the idiopathic form. Indeed the predominant immuno-
globulin deposited in the renal tissue was IgG3, while staining for IgG4
was weak in the absence of circulating anti-phospholipase A2 receptor
(PLA2R) antibodies, possibly implying a distinct process. Moreover, no
detectable immune complexes were found in the patient's serum [4].
On the other hand, we found IgG3 reactivity against superoxide-
dismutase-2 (SOD2) [4], a mitochondrial antioxidant previously identi-
ﬁed as an autoimmune target in patients with idiopathicMN [5]. The ﬁrst
aim of this study was to clarify the role of IgG4 antibodies in our patient's
renal disease, and cellular mechanisms underlying SOD2 enrichment on
the podocyte plasma membrane. We also wanted to establish whether
IgG4-related disease and MN development have a common pathogenic
event. Addressing those questions in our patient and in four other IgG4-
related disease patients without MN, allowed us to recapitulate thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ing. Here we propose a two-stage model in which IgG4 anti-carbonic
anhydrase II (CAII), an autoantigen candidate in IgG4-related disease
patients, is critical for altering pH homeostasis, mitochondrial dynamic,
and SOD2 corticalization. At a later stage, mislocated SOD2 serves as a
target for the binding of IgG3-subtype autoantibodies capable of ﬁxing
complement and amplifying podocyte injury, which contribute to the
MN lesion, likely favored by individual genetic predisposition.
2. Methods
2.1. Study Participants
We analyzed our propositus diagnosed with IgG4-related disease
with autoimmune pancreatitis and Mikulicz disease admitted to the
Nephrology Unit of the Ospedali Riuniti, Bergamo, Italy as reported
[4]. Moreover, we enrolled four additional patients with a diagnosis of
IgG4-related disease. Sera from patients with IgG4-related disease
with tubulointerstitial nephritis (TIN) (IgG4-RD1, IgG4-RD2 and IgG4-
RD4) or without renal involvement (IgG4-RD3) were provided by
Professor Takao Saito (General Medical Research Center, Faculty of
Medicine, Fukuoka University, Japan). The research protocols were ap-
proved by the Ethical Committee of the Clinical Research Center of the
Mario Negri Institute, the Clinical Study Review Board at Fukuoka
University Hospital and the Medical Ethics Committee of Kanazawa
University. Written informed consent was obtained from each patient in
accordance with the Declaration of Helsinki guidelines.
2.2. Total IgG and IgG4 Puriﬁcation
IgG puriﬁcation was performed through afﬁnity chromatography
using Afﬁ-Prep-Protein A (Bio-Rad Laboratories, Hercules, CA) [6].
Serum was centrifuged (11,000 ×g, 20 min) and particulate and lipid
fractions were removed. The sample diluted with binding buffer (gly-
cine 1.5 M–NaCl 3 M, pH 8.9) was loaded on the column and eluted
with citric acid 0.1 M, pH 3. The eluate was concentrated and dialyzed
against PBS (phosphate 10 mM–NaCl 150 mM, pH 7.3) with Amicon
concentrators (Amicon Ultra-15 100 KD, Millipore, Temecula, CA).
IgG4 puriﬁcation was performed using afﬁnity chromatography with
CaptureSelect IgG4 (Hu) afﬁnity matrix (Life Technologies, Carlsbad,
CA) containing a 12 kDa Llama antibody fragment recognizing human
IgG4. The serum was applied to the column and eluted with glycine
0.1 M, pH 3. Sample was concentrated and dialyzed against PBS with
Amicon concentrators. To prevent damage to immunoglobulins due to
exposure to the acidic medium, for both total IgG and IgG4 puriﬁcation,
during the elution step the pH was continuously adjusted to neutrality
by adding 1 M Tris pH 9 to the collecting tube.
2.3. Cell Culture and Incubations
Conditionally immortalized human podocytes (kindly provided
by Prof. M.A. Saleem, Children's Renal Unit and Academic Renal Unit,
University of Bristol, Southmead Hospital, Bristol) were differentiated
for 12 days as previously described [7]. In preliminary experiments,
we found that the patient's serum at the dilution of 1:3 had no cytotoxic
effect (data not shown). Podocyteswere incubated for different time in-
tervals with RPMI 1640 medium (medium), H2O2 (150 μM), patient's
serum (1:3), total IgG (1 mg/ml) or puriﬁed IgG4 (100 μg/ml) from
the patient or from healthy volunteers (n = 3). To document the effect
of the binding of anti-CAII IgG4 on SOD2 expression, podocytes were
exposed for 15 h to anti-CAII antibody (5 μg/ml, Sigma-Aldrich) or to
normal IgG (5 μg/ml, Santa Cruz Biotechnology, Santa Cruz, CA). In addi-
tional experiments, podocytes were exposed for 15 h to the patient's
serum (1:3) that was pre-incubated with puriﬁed CAII (100 μg/ml for
6 h at 4 °C) to saturate the binding of IgG4 anti-CAII. To study the role
of reactive oxygen species in F-actin remodeling, the SOD2 mimeticmanganese (III) tetrakis (4-benzoic acid) porphyrin (mnTBAP)
(100 μM, Santa Cruz Biotechnology) was used. The effect of the car-
bonic anhydrase II inhibitor acetazolamide (500 μM) on intracellular
pH was also investigated. In selected experiments, sera (1:3) from
other patients with IgG4-related disease were used.
2.4. Immunoﬂuorescence Analysis on Cultured Podocytes
Differentiated podocytes were ﬁxed in 2% paraformaldehyde (Elec-
tron Microscopy Science, Hatﬁeld, PA) and 4% sucrose (Sigma-Aldrich,
Milan, Italy) and nonspeciﬁc binding sites were blocked with 2% FBS,
2% bovine serum albumin and 0.2% bovine gelatin in PBS 1×. Cells
were incubated with rabbit polyclonal anti-SOD2 antibody (1:500,
Millipore, Eschborn, Germany) or anti-CAII antibody (1:10,000, Abcam)
followed by incubation with the appropriate Cy3-conjugated secondary
antibody (Jackson ImmunoResearch Laboratories, West Grove, PA).
For colocalization analysis, cells were then incubated with a FITC-
conjugated anti-human IgG3 (1:25, Sigma-Aldrich) or with a FITC-
conjugated anti-C3 (1:25, Dako A/S, Glostrup, Denmark). CAII ex-
pression was evaluated with a rabbit polyclonal anti-CAII antibody
(1:200, Abcam, Cambridge, UK) followed by a goat anti-rabbit Cy3-
conjugated secondary antibody (Jackson ImmunoResearch Laboratories).
To study F-actin rearrangement, ﬁxed podocytes were permeabilized
with 0.3% Triton X-100 (Sigma-Aldrich) and then incubated with
rhodamine-phalloidin (20 U/ml, Molecular Probes Inc., Eugene,
OR). Nuclei were counterstained with DAPI (Sigma-Aldrich). Negative
controlswere obtained by omitting primary antibodies. Sampleswere ex-
amined using a confocal inverted laser microscope (LSM 510Meta; Zeiss,
Jena, Germany). The quantiﬁcation of externalized SOD2 on the plasma
membrane and the count of podocytes with peripheral F-actin distribu-
tion were performed on 15 random ﬁelds per sample. Speciﬁcally, the
area corresponding to the SOD2 staining was measured in pixels by
using the Image J 1.40 g software andnormalized for the number of nuclei
identiﬁed by DAPI staining.
2.5. Podocyte Subcellular Fraction and Whole Extract Preparation
The subcellular fractionation of human podocytes was performed
as previously described [8] withminor modiﬁcations. After incubations,
cells were gently scraped and incubated in hypotonic lysis buffer
(10 mM Tris–HCl pH 7.4, 2 mM EDTA, 200 μM PMSF, 1 mM ben-
zamidine, 10 μg/ml pepstatin and 10 μg/ml leupeptin) for 20 min
on ice and then lysed by sonication. An aliquot of the total cell lysate
(HPE) was saved for Western blot analysis and the remaining sam-
ple was centrifuged (1,000 xg, 10 min, 4 °C) to remove nuclei and
unbroken cells. The supernatant was centrifuged at 31,000 xg for
60 min to pellet crude plasma membranes (CPM).
2.6. Western Blot Analysis
Podocyte whole extracts (20 μg), membrane extracts (20 μg), re-
combinant human GST-tagged carbonic-anhydrase-II (rhCAII, 0.5 μg;
Abnova, St. Taipei, Taiwan) were electrophoresed on 12% SDS-PAGE
under reducing conditions and blotted on PVDF membrane (Bio-Rad
Laboratories). The membranes were blocked with 0.1% TWEEN 20 and
0.5% powdered milk in PBS 1×. The reactivity of sera from patients
with IgG4-related disease and healthy subjects (n = 6) against CAII
was tested by blotting membranes with serum diluted 1:10 followed
by mouse anti-human IgG4-HRP antibody (clone HP6025, 1:1,000;
Life Technologies, Gaithersburg, MA). To conﬁrm the speciﬁc reactivity
of IgG4 against CAII, membranes were stripped and reprobed with a rab-
bit anti-human CAII antibody (1:10,000; Abcam) followed by a goat anti-
rabbit IgG-HRP (1:5,000; Sigma-Aldrich) antibody. To assess the reactivity
of sera from patients with IgG4-related disease against SOD2, recombi-
nant human GST-tagged SOD2 (rSOD2, 0.6 μg, Abnova) was electropho-
resed as above and membranes were blotted with serum diluted 1:10
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nologies). To screen the reactivity of IgG subclasses against SOD2 and
CAII in patients' sera, recombinant human GST-tagged SOD2 (rSOD2,
0.6 μg, Abnova) and puriﬁed CAII (pCAII, 0.5 μg, Sigma-Aldrich)were elec-
trophoresed as above and membranes were blotted with patient's serum
diluted 1:10 followed by mouse anti-human IgG1-HRP antibody (clone
HP6069, 1:1,000; Life Technologies), mouse anti-human IgG2-HRP
antibody (clone HP6014, 1:500; Life Technologies), mouse anti-
human IgG3-HRP antibody (clone HP6047, 1:500; Life Technologies)
and mouse anti-human IgG4-HRP antibody (clone HP6025, 1:1,000; Life
Technologies). Bands were visualized with the ECL Western blotting
Detection Reagent (Pierce/Celbio, Pero, Italy).
2.7. Intracellular pH Determination
Themethodwas previously described [9] and calibrated by using the
following procedure. Podocytes were loaded with 8 μM BCECF-AM
(Molecular Probes, Invitrogen) for 15 min in RPMI 1640 medium at
37 °C. The cells were washed and incubated for 10 min with a modiﬁed
Ringer solution adjusted to different pH values (125 mM KCl, 1 mM
MgCl2, 1 mM CaCl2, 20 mM Hepes) supplemented with nigericin
(10 μM, Molecular Probes, Invitrogen). The ﬂuorescence intensities
were then determined at the cellular level by themultimodemicroplate
reader TECAN Inﬁnite M200® PRO (Tecan Group Ltd., Mannedorf,
Schweiz) at an excitation wavelength of 490 nm and emission wave-
length of 530 nm, and the values were used to generate a calibration
curve. To evaluate changes in intracellular pH after podocyte stimula-
tion, cells were incubated with 8 μM BCECF-AM in the last 15 min of
the stimuli. The ﬂuorescence intensity was determined as above and
the intracellular pH was extrapolated from the calibration curve.
2.8. Mitochondrial Morphology and Membrane Potential Detection
The ﬂuorescent probe MitoTracker® Red (Molecular Probes,
Invitrogen), which covalently binds to mitochondrial proteins by
reacting with free thiol groups of cysteine residues regardless of mem-
brane potential, and JC-1 (Molecular Probes, Invitrogen), a mitochondrial
membrane potential sensor, were used to monitor mitochondrial mass
and membrane potential, respectively. The MitoTracker® (250 nM) or
JC-1 (5 μg/ml) was added to podocytes in the last 30 min of the stimuli.
Cells were then rinsed twice in cold PBS 1× and ﬁxed. Nuclei were coun-
terstained with DAPI. Samples were examined under confocal inverted
laser microscopy (LSM 510 Meta).
2.9. Mitochondrial ROS Production
Mitochondrial ROS were measured using MitoSOX™ Red, a live-
cell-permeant mitochondrial superoxide indicator (Molecular Probes,
Invitrogen). Cells were exposed to 5 μM MitoSOX added to the me-
dium for the ﬁnal 30 min of the treatment. Cells were collected by
trypsinization, washed and mitochondrial superoxide was determined
by FACS (FACS Canto, BD Biosciences,MI, Italy). MitoSOX Redwas excited
by laser at 510 nmwavelength and data collected at 580 nm (FL2) chan-
nel. The data were expressed as mean intensity of MitoSOX ﬂuorescence
and % of MitoSOX ﬂuorescent cells.
2.10. Cell Fixation and Embedding for Electron Microscopy
Cells seeded on Thermanox coverslips were ﬁxed in 3.5% paraformal-
dehyde and 0.01% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4, and
then embedded in LRWhite resin (ElectronMicroscopy Sciences) accord-
ing to the standard protocol. Brieﬂy, cellswere quickly dehydrated in a se-
ries of ethanol solutions (30, 40, 50, 60, 70%; 10 min each), and then
incubated with a mix of 70% ethanol/resin (1:1) for 30 min, followed by
pure resin. Samples were inﬁltrated overnight with a fresh portion ofpure resin at 4 °C and then LR White resin was polymerized at 4 °C
under UV light.
2.11. Immunogold Labeling
Fragments of kidney biopsies from the archives of the Nephrology
Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy, were
ﬁxed in 3.5% paraformaldehyde and 0.01% glutaraldehyde in 0.1 M
phosphate buffer, pH 7.4, dehydrated through ascending grades of alco-
hol and embedded in LRW resin (Electron Microscopy Sciences, EMS).
Ultrathin sections (120 nm thick) were cut and mounted on 100-
mesh copper grids. Antigen retrieval was performed in 10 mM citrate
buffer, pH 6.0, and microwaved for 4–5 min. Non-speciﬁc labeling was
blocked by 1% BSA in PBS and then sections were incubatedwith primary
antibodies rabbit anti-human SOD2 (1:100; Millipore) and rabbit anti-
human CAII (1:5,000, Abcam) followed by 12-nm gold conjugated goat
anti-rabbit IgG (1:20; Jackson ImmunoResearch Laboratories). Sections
were then contrasted with uranyl acetate. Ultrathin sections were exam-
ined and images were acquired using a Philips Morgagni transmission
electron microscope (FEI Company, Eindhoven, The Netherlands).
2.12. Immunoﬂuorescence Analysis on Renal Tissue
Kidney biopsy from our patient from the archives of Nephrology
Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy, was
snap-frozen in liquid nitrogen, embedded in OCT compound and used
for immunoﬂuorescence analysis. In addition, renal biopsies from an
uninvolved portion of kidney collected from tumor nephrectomy
specimens were obtained from 8 patients and used as controls. Written
informed consent was obtained from all these patients. Sections (3 μm)
were air-dried, ﬁxed with cold acetone and washed with PBS. After
blocking non-speciﬁc sites with 1% BSA, slideswere incubatedwith rab-
bit anti-human SOD2 (1:50, Millipore), rabbit anti-human CAII (1:600,
Abcam) and mouse anti-human podocalyxin (1:150, gift from Pro-
fessor Robert Atkins, Department of Nephrology, Monash Medical
Centre, Clayton, VIC, Australia) followed by the species-speciﬁc
Cy3 or FITC-conjugated secondary antibodies (Jackson Immunoresearch
Laboratories). IgG4 deposits were immunolocalized by FITC-conjugated
anti-human IgG4 (1:50, Sigma-Aldrich). Nuclei were stained with DAPI.
Negative controlswere obtained by omitting primary antibodies fromad-
jacent sections. Fluorescence was examined using an inverted confocal
laser scanning microscope (LMS 510 Meta). Z-stack glomerular images
were collected with a spacing of 0.37 μm. The co-localization areas were
visualized in each confocal optical sectionwithin the Z-stack by using ap-
propriate software (LSM 510 Meta).
2.13. Electron Microscopy Analysis of Mitochondria in Renal Biopsy
Renal biopsy samples were processed using the standard technique
for transmission electron microscopy. Brieﬂy, the fragments (1 mm3)
were ﬁxed in 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4),
postﬁxed in 1%osmium tetroxide, and dehydrated in alcohol for embed-
ding in Epon resin. Ultrathin sections (100 nm) were cut on an EM UC7
ultramicrotome (Leica Microsystems, Mannheim, Germany), collected
on copper grids, and stained with uranyl acetate and lead citrate for
analysis.
2.14. Statistical Analysis
Results are expressed as mean ± SE. Data analysis was performed
using the computer software Prism (GraphPad Software Inc., San
Diego USA). Comparisons were made by analysis of variance (ANOVA)
with Tukey post hoc test or unpaired or paired Student's T test as appro-
priate. Statistical signiﬁcance was deﬁned as P b 0.05.
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3. Results
3.1. Patient parameters
Patient IgG4-RD1 is a 73-year-old male with a diagnosis of IgG4-
related disease involving the lung and TIN. His laboratory parameters
at time of sampling were: serum creatinine 0.79 mg/dl, protein excre-
tion 77 mg/gCr, total IgG 3426 mg/dl and IgG4 1230 mg/dl.
Patient IgG4-RD2 is a 61-year-old male with a history of IgG4-related
disease involving the lacrimal glands, salivary glands, and lung. In this pa-
tient a diagnosis of TIN was made. The patient suffered from a MALT-
lymphoma and underwent surgery for a renal carcinoma. At time of sam-
pling laboratory parameters were: serum creatinine 1.32 mg/dl, protein
excretion 500 mg/gCr, total IgG 1876 mg/dl and IgG4 628 mg/dl.
Patient IgG4-RD3 is 54-year-old female with IgG4-related disease
involving the lung, lymph nodes and aorta. She had autoimmune pan-
creatitis. The following values of laboratory parameters were found at
the time of sampling: serum creatinine 0.71 mg/dl, protein excretion
negative, total IgG 1968 mg/dl and IgG4 536 mg/dl.
Patient IgG4-RD4 is a 75-year-oldmalewith IgG4-related disease in-
volving the lacrimal glands and aorta. He suffered from autoimmune
pancreatitis and is affected by TIN. His laboratory parameters at time
of sampling were: serum creatinine 1.34 mg/dl, protein excretion
0.2 g/day, total IgG 5380 mg/dl and IgG4 587 mg/dl.
3.2. The Patient's IgG4 Speciﬁcally Recognizes Carbonic Anhydrase II on
Cultured Podocytes
We found that IgG4 in our patient's serum recognized a recombinant
GST-tagged CAII proteinwith amolecularweight of 55 kDa (Fig. 1A, ﬁrst
lane) as well as a 30 kDa protein corresponding to CAII in protein ex-
tracts from cultured human podocytes (Fig. 1A, second and third
lanes, arrowhead). The possible existence of other unknown antigens
could not be excluded because the patient's IgG4 also recognized
other bands in the podocyte extracts (Fig. 1A, second lane). No IgG4 re-
activity against CAII was found in sera from healthy subjects (Fig. 1A,
right lane). Western blot analysis of puriﬁed CAII protein revealed that
IgG4 was the predominant IgG subclass of anti-CAII antibodies in the
patient's serum while reactivity of other IgG subclasses was absent
(Fig. 1B). In podocytes, CAII clearly localized in the cytoplasm and at
the cell periphery of permeabilized cells (Fig. 1C, left). We also found
high CAII membrane expression in non-permeabilized cells (Fig. 1C,
middle). CAII membrane localization was conﬁrmed by the detection
of a 30 kDa band using Western blotting in podocyte crude plasma
membranes (Fig. 1C, right). Immunogold labeling conﬁrmed CAII cyto-
plasmic and membrane expression in podocytes in a control subject's
biopsy as shown in Fig. 1D.
3.3. Glomerular Expression of CAII in Healthy Controls and in IgG4-Related
Disease Patient
Granular CAII was revealed in the glomeruli of control kidney biop-
sies (Fig. 2A) andwas increased in the patient's sample, showing a gran-
ular pattern along the glomerular capillary walls (Fig. 2B). CAII was also
expressed in tubuli of both control subjects, as previously reported [10]
and the IgG4-related disease patient (Fig. 2A and B). Double immuno-
staining with CAII and the podocyte marker podocalyxin showed that
CAII localized in podocytes (Fig. 2C). The co-localization was also con-
ﬁrmed in z-axis, as reported in Supplementary Fig. 1. In patient's glo-
meruli, double immunostaining documented that CAII stronglycolocalized with deposited IgG4 (Fig. 2D). The co-localization between
CAII and IgG4 was robust, albeit partial, and consistently present along
the z-axis (Supplementary Fig. 2). Triple immunostaining revealed
that CAII and IgG4 colocalizedwith podocalyxin (Fig. 2E). No IgG4 stain-
ing was found in renal biopsies of control subjects (Supplementary
Fig. 3).
3.4. Patient's IgG4 Induces Cell Acidiﬁcation, Mitochondrial Dysfunction
and Cytoskeletal Remodeling in Podocytes
Based on the role of CAII in maintaining cellular pH [11], we asked
whether the patient's IgG4 could interferewith intracellular pH control.
We compared the effect of acetazolamide, a known CAII pharmacologic
inhibitor, on intracellular pHwith that of IgG4 immunopuriﬁed from the
patient's serum. The intracellular pH time-dependently decreased in
culturedpodocytes after acetazolamide exposure (Fig. 3A). The patient's
IgG4, but not the IgG4 isolated fromhealthy volunteers (control's IgG4),
caused a pronounced drop in pH to very low levels, reproducing an even
more powerful effect than that reached by the CAII inhibiting action of
acetazolamide (Fig. 3A). Immunoﬂuorescence analysis in cultured
podocytes showed fragmentation of the mitochondrial network after
exposure to the patient's IgG4, but not to the control's (Fig. 3B, left).
This was associatedwith collapse ofmitochondrial membrane potential
(Fig. 3B, right) as revealed by a red-to-green shift of the ﬂuorescence
emission of themitochondrial potential-sensitive probe. A similar effect
on mitochondria was observed in podocytes exposed to hydrogen per-
oxide (H2O2) (Fig. 3B), known to generate reactive oxygen species
(ROS), which mediate mitochondrial dysfunction. Electron microscopy
analysis of the patient's renal biopsy showed mitochondrial alterations
with matrix loss and cristae disorganization, which appears rather con-
sistent with the in vitro ﬁndings. Those changes were variably associat-
ed with dense cytoskeletal-like cytoplasmic strands and junctional
abnormalities (Fig. 3C). Podocyte exposure to either IgG4 from our
patient or H2O2 triggered mitochondrial generation of superoxide
anion as detected by the ﬂuorescent dye MitoSOX at both 6 and 15 h
(Fig. 3D and Supplementary Fig. 4). The patient's IgG4 induced only at
15 h a corticalization of F-actin ﬁlaments that, in contrast, were distrib-
uted across the cell body in the unstimulated or control's IgG4-treated
podocytes (Fig. 3E). H2O2 also caused F-actin rearrangement to a lesser
extent than the patient's IgG4 (Fig. 3E), suggesting a role for oxidative
stress in cytoskeletal alteration. This was conﬁrmed by the addition of
the antioxidant MnTBAP, a mitochondrial-targeted SOD2-mimetic,
which prevented F-actin corticalization in podocytes incubated with
the patient's IgG4 (Fig. 3E).
3.5. Immunocompetent IgG4 Leads to SOD2 Mislocation on the Plasma
Membrane Favoring Complement Deposition
Given that the antioxidant SOD2-mimetic reverted the effect of the
patient's IgG4 on ROS-dependent cytoskeletal remodeling upon binding
to CAII, and that SOD2 has previously been identiﬁed as a plasmamem-
brane antigen for the IgG3 of this patient [4], we investigated the causal
link between IgG4 anti-CAII and themitochondrial SOD2 on the plasma
membrane of injured podocytes. Exposure to the patient's IgG4 or H2O2
resulted in a signiﬁcant increase in SOD2 staining on the podocyte sur-
face (Fig. 4A and B). However, only the patient's IgG4 was able to elicit
the SOD2 cluster formation on the podocyte membrane (Fig. 4A and
C). The control's IgG4 had no effect (Fig. 4A–C). The patient's IgG4-
induced SOD2 externalization was dependent on mitochondrial dys-
function, since Cyclosporin A – an inhibitory agent of themitochondrial
permeability transition pore [12] – signiﬁcantly attenuated SOD2 expres-
sion on the podocyte surface (Supplementary Fig. 5). To further prove the
functional link between anti-CAII antibody and SOD2 externalization,
non-permeabilized cultured human podocytes were incubated with a
speciﬁc anti-CAII antibody. After 15-hour incubation, a strong presence
of SOD2 at the podocyte surface was observed (Fig. 4D, middle panel).
Fig. 1. Patient's IgG4 recognized CAII on podocytes. (A)Western blotting of the 55 kDa recombinant humanGST-tagged CAII (rhCAII, 0.5 μg) or human podocyte extracts (HPE, 20 μg)with
patient's (ﬁrst and second lanes) or control's serum (fourth lane). IgG-subclass speciﬁcity was evaluated using an anti-human IgG4-HRP antibody. The HPE membrane was stripped and
reprobed with a speciﬁc anti-human CAII antibody (third lane). Molecular weights (kDa) shown on the left side. (B)Western blotting of puriﬁed CAII (pCAII, 0.5 μg) and the recombinant
human GST-tagged SOD2 (rSOD2, 0.6 μg) with patient's serum. IgG-subclass speciﬁcity was evaluated using an anti-human IgG1-HRP antibody, anti-human IgG2-HRP antibody,
anti-human IgG3-HRP antibody or anti-human IgG4-HRP antibody. (C) CAII expression evaluated using immunoﬂuorescence analysis (left) or Western blotting (right) of podocyte
crude plasma membranes (CPM, 20 μg). Scale bars 20 μm. (D) CAII immunogold staining in normal human kidney.
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normal IgG (Fig. 4D, right panel). In an additional set of experiments, cul-
tured human podocytes were exposed to patient's serum either alone or
following pre-exposure to puriﬁed CAII to speciﬁcally saturate the CAII
binding sites of the patient's IgG4. The patient's serum alone elicited the
formation of clustered SOD2 on the cell surface (Supplementary Fig. 6),effect that was not obtained when the patient's serum was previously
pre-incubated with puriﬁed CAII (Supplementary Fig. 6).
To test the possibility that surface-exposed SOD2 could be recog-
nized by anti-SOD2 IgG3 present in the patient's serum [4], we veriﬁed
the co-localization of SOD2 and IgG3 on non-permeabilized podocytes.
Similarly to the patient's IgG4, total IgG puriﬁed from the patient's
Fig. 2. Glomerular CAII increased and co-localized with IgG4 deposits in podocytes in patient's biopsy. (A and B) Representative images of CAII immunoﬂuorescence in controls' (A) and
patient's (B) glomeruli. (C) Co-localization between CAII (red) and PDX (white) in patient's sample. (D) Co-localization between CAII (red) and IgG4 (green) in patient's sample. (E) Triple
immunostaining for CAII, IgG4 and PDX in patient's glomerulus. The details of the co-localization areas highlighted in insets are shown enlarged below, and indicated by arrows. Nuclei
were stained with DAPI. Scale bars 50 μm.
461S. Buelli et al. / EBioMedicine 2 (2015) 456–466serum promoted externalization of SOD2 that co-localized with IgG3 de-
posited with a granular distribution on podocyte membranes (Fig. 5A,
upper panels). Immunoelectron microscopy of cultured podocytes con-
ﬁrmed that SOD2 was conﬁned to the mitochondria of the control's IgG-
treated podocytes while it was consistently found on the plasma
membrane in cells exposed to the patient's IgG (Fig. 5A, lower panels).
The patient's serum, as a source of complement and IgG, also induced
complement activation and C3 recruitment to SOD2 (Fig. 5B). No effects
were observed when the control's IgG or sera were used (Fig. 5A and
B). To further assess the potential role of the SOD2/anti-SOD2 system in
theMNpattern found in our patient,we determined the glomerular local-
ization of SOD2 in biopsy tissue. SOD2 was not detectable in normal kid-
ney glomeruli. We found granular peripheral SOD2 staining along the
patient's glomerular capillarywalls (Fig. 5C). This staining inMN reﬂected
extracellular localization and accumulation of both antigen and anti-
SOD2 antibodies in subepithelial deposits [5]. We found an identical
granular pattern for IgG3, which is the predominant subtype within our
patient's deposits. Notably, IgG3 is the anti-SOD2 IgG subtype detected
in the patient's blood [4].
To verify the potential pathogenic role of the IgG4-dependent intra-
cellular mechanisms identiﬁed, we extended our observations to other
IgG4-related disease patients. In a set of four untreated IgG4-related
disease patients, we identiﬁed three sera containing IgG4 anti-CAII
and onenegative for these autoantibodies (Fig. 6A). Similarly to our pro-
positus' serum, only CAII-positive sera were able to elicit a drop inintracellular pH (Fig. 6B), markedly externalize SOD2 (Fig. 6C, left
panel), and cluster it on the podocyte membrane (Fig. 6C, right
panel). Despite the effect of autoreactive IgG4 anti-CAII on SOD2 ex-
pression in podocytes, we detected no IgG3 anti-SOD2 in any tested
sera (Fig. 6D).
4. Discussion
The majority of patients with IgG4-related disease, particularly when
associated with autoimmune pancreatitis, have circulating IgG4 subclass
antibodies that recognize CAII [13,14]. The patient with hyper-IgG4 de-
scribed here does indeed have both circulating IgG4 reacting with CAII
and MN, and we disclose a functional link between the binding of the
patient's IgG4 to podocytes and the intracellular events underlying the
development of the MN lesion. CAII is expressed in most segments of
the human kidney, including proximal and distal tubules [10]. In addition
to its typical cytosolic distribution, CAII has been found to localize close to
the plasma membrane where it interacts with the electroneutral Cl−/
HCO3− anion exchanger 1, giving rise to a transport metabolon wherein
HCO3− is transferred from CAII to the anion exchanger, maximizing its
cotransporter activity [15].
Herewe found that podocytes, both in vitro and in kidney-biopsy tis-
sue sections, express CAII. Furthermore, IgG4 puriﬁed from the patient's
serum elicits early intracellular acidiﬁcation with profound effects on
podocyte homeostasis as a likely consequence of the interaction of IgG4
Fig. 3. Cell acidiﬁcation, mitochondrial alterations and ROS-dependent cytoskeletal dysfunction induced by patient's IgG4. (A) Fluorimetric assay detecting intracellular pH in podocytes
exposed to control's or patient's IgG4 (100 μg/ml), control medium (medium) or acetazolamide (ACZT, 500 nM). °°p b 0.01 vs control's IgG4; *p b 0.05, **p b 0.01 vs medium (n = 4
experiments). (B) Representative images of mitochondria labeled with MitoTracker (left panel) or the mitochondrial membrane potential sensor JC-1 (right panel) in podocytes exposed
6 h to control's or patient's IgG4 (100 μg/ml), control medium (medium) or H2O2 (150 μM). JC-1 accumulates in intact mitochondria resulting in a red emission, while it presents diffuse
cytosolic green ﬂuorescence in cells with depolarized mitochondria. Nuclei were stained with DAPI (blue). Scale bars 20 μm. (C) Electron micrographs of mitochondria (arrows) in
podocyte from control's and our propositus' biopsy, showing reduced density of matrix and loss of cristae. P, podocyte; GBM, glomerular basement membrane; d, subepithelial
electron-dense deposit. (D) Mitochondrial oxidative stress assessed as O2•− generation using MitoSOX ﬂow cytometry measuring mean ﬂuorescence intensity (MFI). Results are
mean ± SE. °p b 0.05, °°p b 0.01 vs control's IgG4; *p b 0.05, **p b 0.01 vs medium (n = 3 experiments). (E) Representative images and quantiﬁcation of F-actin (red) rearrangement
in podocytes exposed 15 h to control's or patient's IgG4 (100 μg/ml), control medium (medium), or H2O2 (150 μM). Nuclei were stained with DAPI (blue). Scale bars 50 μm. In additional
experiments, MnTBAP (100 μM) was used. Results (mean ± SE) are expressed as percentage of cells with F-actin rearrangement. °°p b 0.01 vs control's IgG4; *p b 0.05 vs medium;
##p b 0.01 vs patient's IgG4 (n = 4 experiments).
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even greater than the acidiﬁcation elicited by a speciﬁc pharmacologic
CAII inhibitor, indicating direct and potent inhibitory action of the
patient's IgG4 on podocyte CAII that can behave as a functional pathogen-
ic target. Notably, this interaction is reminiscent of the ability of non-complement-ﬁxing IgG4 autoantibodies to interact with an antigen
in terms of inhibiting its function, as has been shown for IgG4 to
muscle-speciﬁc kinase in patients with myasthenia gravis [16,17] and
suggested for anti-PLA2R antibodies in patients with idiopathic MN [18,
19]. In this regard, in the case of our patient, the co-localization of CAII
Fig. 4. Patient's IgG4 leads to SOD2 externalization to podocyte plasma membrane. (A) Representative images of SOD2 expression (red) on the surface of cultured human podocytes
exposed 15 h to control's or patient's IgG4 (100 μg/ml), control medium (medium) or H2O2 (150 μM). Clustered SOD2 is indicated with arrowhead. Nuclei were stained with DAPI
(blue). Scale bars 50 μm. (B, C) Histograms show quantiﬁcation of surface staining (B) and mean average size (C) of SOD2 clusters on podocyte plasma membrane expressed as
mean ± SE. °p b 0.01 vs control's serum; *p b 0.01 vs medium (n = 8 experiments). (D) Representative images of SOD2 expression (red) on the surface of cultured human podocytes
exposed for 15 h to control medium (medium), commercially available anti-CAII antibody (5 μg/ml), or normal IgG (5 μg/ml). Nuclei were stained with DAPI (blue). Scale bars 50 μm.
(n = 3 experiments).
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Fig. 5. Patient's IgG3, by binding externalized SOD2, favored complement activation. (A,
upper panel) Co-localization (yellow) of SOD2 (red) and IgG3 (green) on non-permeabilized
podocytes exposed to total IgG fraction (1mg/ml) immunopuriﬁed fromcontrol's orpatient's
serum. Nuclei were stainedwith DAPI (blue). Scale bars 50 μm. (A, lower panel) Representa-
tive electronmicrographs of immunogold labeling of SOD2 in podocytes exposed to control's
or patient's total IgG fraction. Gold particles localized on the plasma membrane in patient's
IgG-treated cells (arrowheads). (B) Co-localization (yellow) of SOD2 (red) and complement
C3 (green) on non-permeabilized podocytes exposed to control's or patient's serum. Nuclei
were stained with DAPI (blue). Scale bars 50 μm. (C) Immunoﬂuorescence analysis
of SOD2 (red) renal expression in control's and in our IgG4-related disease patient's
biopsy. Nuclei were stained with DAPI (blue). Scale bars 50 μm.
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in the subepithelial immune deposits. This observation offers an impor-
tant clue, which suggests that anti-CAII antibodies, which in our patient
are restricted to the IgG4 subtype, could be responsible for initiating the
disease.
Relying on evidence of mitochondrial disruption after early acid-
iﬁcation in response to injurious stimuli [20], we next analyzed the
consequences of low pH on mitochondrial functions. Our data that
the decrease of podocyte pH preceded mitochondrial alteration
and fragmentation provide a link between IgG4-driven intracellular
acidiﬁcation and perturbation of mitochondrial dynamics. Mitochondrial
dysfunction in IgG4-treated podocytes was associated with massive ROS
production, which in turn promoted F-actin cytoskeletal alterations.
In this regard, an important role for ROS in inducing cytoskeletal reorga-
nization in injured podocytes has been documented [21].
Another major ﬁnding of the study consists in the externalization of
the mitochondrial enzyme SOD2 in clusters in direct response to the
patient's IgG4-CAII ligation in vitro. The causal role of IgG4 anti-CAII
challenge on SOD2 externalization is provided by the combined evi-
dence that incubating the cells with an anti-CAII antibody induced the
mislocation of SOD2 on the podocyte surface and that the saturation
of patient's serum antibodies with puriﬁed CAII prevented the SOD2
mobilization. This would indicate a direct effect of the patient's IgG4
anti-CAII in the activation of intracellular signaling that leads to SOD2
trafﬁcking to the podocyte plasmamembrane. The observedmitochon-
drial fragmentation along with the consequent altered membrane po-
tential in response to anti-CAII IgG4 could affect the release of matrix
proteins from failing mitochondria [22], including SOD2. The ﬁnding
that prevention of mitochondrial depolarization attenuated IgG4-
induced SOD2 externalization on the membrane of damaged podocytes
points to mitochondrial dysfunction as the major cause of SOD2 mislo-
cation after exposure to the patient's IgG4.
Protein membrane trafﬁcking in podocytes is regulated by cytoskel-
etal F-actin ﬁlaments [23] and cytoskeletal alterations have been associ-
ated with SOD2 mistargeting from spoiled mitochondria to the cell
surface [24]. Here we suggest that the patient's IgG4-induced cytoskel-
etal F-actin corticalization could drag the released SOD2 toward the
plasma membrane and inﬂuence its spatial patterning in podocytes. In
line with our ﬁndings, a local enrichment of cortical actin ﬁlaments
was found to regulate nanocluster formation of membrane proteins
[25]. The role of cytoskeletal remodeling in SOD2 cluster formation
rests on the evidence that H2O2, while promoting strong SOD2 external-
ization, did not induce the SOD2 cluster formation. This difference could
conceivably be a consequence of the lower capacity of H2O2 to induce
F-actin corticalization compared to IgG4. The consequent C3 deposition
on the cell surface indicates that the externalized SOD2 is the target for
the binding of the patient's IgG3, leading to complement activation.
Since SOD2 becomes recognizable on the podocyte surface via a process
that can be related to the patient's IgG4 and is induced with disease,
SOD2 behaves like a neoantigen, as other intracellular proteins, which
are not abundantly expressed in the normal glomerulus [19]. Given the
absence of detectable circulating immune complexes in our patient and
according to known disease models, these ﬁndings converged to suggest
intraglomerular interaction between IgG3 and SOD2 further shaping the
MN lesion in the presence of anti-CAII IgG4 (see scheme Fig. 6E).
Although SOD2 has been suggested as a possible neoantigen in
non-PLA2R associated MN, it is not clear whether or not the anti-SOD2
antibodies could worsen the existing disease or be informative as to
its immunologic duration [19]. Together, our data lend further support
to the view that SOD2 is not a primary antigen inMN, and in our patient.
On the other hand, the early nature of anti-CAII IgG4-dependent
podocyte injury could be suggested by ﬁndings that among additional
patients with IgG4-related disease, only the sera of those with IgG4
anti-CAII antibodies promoted in vitro externalization and clustering of
SOD2. The fact that not all of them could develop full-blown MN can
be explained by multiple factors that possibly include genetic risks,
Fig. 6. Effect of IgG4 anti-CAII in sera of untreated IgG4-related disease patients. (A) Western blotting of puriﬁed CAII (pCAII, 0.6 μg). IgG-subclass speciﬁcity against CAII was evaluated
using an anti-human IgG4-HRP antibody. (B) Intracellular pH detected using ﬂuorimetric assay in podocytes exposed 6 h to IgG4 anti-CAII positive sera (CAII+ sera), IgG4 anti-CAII neg-
ative serum (CAII− sera), control's serum (control's serum) or control medium (medium). °°p b 0.01 vs control's IgG4; *p b 0.05, **p b 0.01 vs medium (n = 4 experiments).
(C) Histograms show the quantiﬁcation of surface staining (left) and the mean average size of the SOD2 clusters (right) expressed as mean ± SE. °p b 0.01 vs control's serum;
*p b 0.01 vs medium (n = 8 experiments). (D) Western blotting of recombinant SOD2 (rSOD2, 0.6 μg). IgG-subclass speciﬁcity against SOD2 was evaluated using an anti-human IgG3-
HRP antibody. (E) Schematic representation of the proposed mechanism by which IgG4 promotes podocyte dysfunction, SOD2 externalization on the plasma membrane and C3-ﬁxing
IgG3 deposition. CAII, carbonic-anhydrase-II; C3, complement component 3; GBM, glomerular basement membrane; kAE1, kidney anion exchanger 1; ROS, reactive oxygen species.
465S. Buelli et al. / EBioMedicine 2 (2015) 456–466epitope spreading, preformedor natural IgG against SOD2, duration, or in-
sults such as a microbial infection as suggested for PLA2R-associated MN
[19]. Duration in particular might be important both in primary and sec-
ondary forms of the disease. In patients with autoimmune pathologies
like systemic lupus erythematosus, a series of autoimmune changes
leads to the appearance of different autoantibodies that usually precede
the onset of clinical illness bymany years [26]. Remarkably in this context,
in all IgG4-related disease patients described to date, CAII antibodieswere
mutually exclusive with PLA2R antibodies, like the recently recognizedThrombospondin Type-1 Domain-Containing 7A antibodies do in idio-
pathic MN patients [27], which would be entirely consistent with CAII
as a primary target in podocytes at least in our patient.
Advances in identifying novel biomarkers, including serological sig-
natures and early key autoantibodies, provide a predictable tool for diag-
nosing and screening for disease while patients are still asymptomatic.
Likewise, the identiﬁcation of autoantibodies involved in early-stage MN
pathogenesis, possibly including IgG4 anti-CAII antibodies in a sub-
set of patients, may provide a crucial site for potential therapeutic
466 S. Buelli et al. / EBioMedicine 2 (2015) 456–466intervention to halt the initial MN lesions and the ensuing clinical
onset of the pathology.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.03.003.
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